119th Congress · introduced in the Senate · Mar 17, 2026
Stem Cell Therapeutic and Research Reauthorization Act of 2026
Official title from Congress.gov
Latest action (Jun 22, 2026): Placed on Senate Legislative Calendar under General Orders. Calendar No. 443.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Reported to Senate (Jun 22, 2026)
Stem Cell Therapeutic and Research Reauthorization Act of 2026
This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA).
The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research. The bill also expands periodic reviews of the state of stem cell science to specifically include a review of the use of high-quality cord blood units and other emergent technologies to develop new therapies for potential inclusion in the program.
Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 443.
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1093)
Introduced in Senate
Actions from Congress.gov, newest first.
Biological and life sciences · Blood and blood diseases · Cell biology and embryology · Health programs administration and funding · Organ and tissue donation and transplantation
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
22 citations.
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Family issues/Abortion/Adoption
$310,000
Spent on own lobbying
…Patients Deserve Price Tags Act H.R.5485 - Second Chance at Life Act H.R.8119- HOPE with Fertility Services Act S.4507, H.R.8784 - Bereaved Parents Rights Act S.4109 - Stem Cell Therapeutic and Research Reauthorization Act of 2026 S.3799, H.R.3302 - Healthy Start Reauthorization Act of 2026 H.R.8239 - SACRED Act S.4880, H.R…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$310,000
Spent on own lobbying
…Patients Deserve Price Tags Act H.R.5485 - Second Chance at Life Act H.R.8119- HOPE with Fertility Services Act S.4507, H.R.8784 - Bereaved Parents Rights Act S.4109 - Stem Cell Therapeutic and Research Reauthorization Act of 2026 S.3799, H.R.3302 - Healthy Start Reauthorization Act of 2026 H.R.8239 - SACRED Act S.4880, H.R…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL MARROW DONOR PROGRAM · lobbying firm or registrant: NATIONAL MARROW DONOR PROGRAM
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$310,000
Spent on own lobbying
Reauthorization of C.W. Bill Young Cell Transplantation Program (House and Senate), H.R. 5160/S. 4109. Clinical Trial Modernization Act, H.R. 3521, S. 4440. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to en…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NEW YORK BLOOD CENTER ENTERPRISES · lobbying firm or registrant: ARNOLD & PORTER KAYE SCHOLER LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$20,000
Paid to lobbying firm
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (H.R. 5160/S. 4109).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NMDP · lobbying firm or registrant: VAN SCOYOC ASSOCIATES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$110,000
Paid to lobbying firm
….R.5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025, Cellular Transplant related issues and initiatives; and Reauthorization related issues S.4109, Stem Cell Therapeutic and Research Reauthorization Act of 2026, Entirety Transplant related issues, generally Monitor the following: Transplant courier issues…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MEDICAL COLLEGE OF WISCONSIN · lobbying firm or registrant: VAN SCOYOC ASSOCIATES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Medical/Disease Research/Clinical Labs
$40,000
Paid to lobbying firm
…th and Human Services, and Education, and Related Agencies Appropriations Act, 2027, Healthcare research and development related issues; and NIH indirect costs S.4109, Stem Cell Therapeutic and Research Reauthorization Act of 2026, Entirety
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTCT · lobbying firm or registrant: SMITHBUCKLIN CORPORATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Health Issues
$70,000
Paid to lobbying firm
…ns Billing and Coding classifications CAR-T Therapy Clarifications OMB Uniform Guidance Oversight H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160/S.4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act S. 4440/H.R. 3521 - The Clinical Trial Moderniza…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COLLEGE OF AMERICAN PATHOLOGISTS · lobbying firm or registrant: COLLEGE OF AMERICAN PATHOLOGISTS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Health Issues
$203,130
Spent on own lobbying
…provider payments under the Medicare program S.4254 - A bill to amend the Public Health Service Act to provide for a health care workforce innovation program. S.4109 - A bill to reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes S.4110 - A bill to revise and extend health workforce progra…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Family issues/Abortion/Adoption
$420,000
Spent on own lobbying
…Patients Deserve Price Tags Act H.R.5485 - Second Chance at Life Act H.R.8119- HOPE with Fertility Services Act S.4507, H.R.8784 - Bereaved Parents Rights Act S.4109 - Stem Cell Therapeutic and Research Reauthorization Act of 2026 S.3799, H.R.3302 - Healthy Start Reauthorization Act of 2026 H.R.8239 - SACRED Act S.4880, H.R…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Health Issues
$420,000
Spent on own lobbying
…Patients Deserve Price Tags Act H.R.5485 - Second Chance at Life Act H.R.8119- HOPE with Fertility Services Act S.4507, H.R.8784 - Bereaved Parents Rights Act S.4109 - Stem Cell Therapeutic and Research Reauthorization Act of 2026 S.3799, H.R.3302 - Healthy Start Reauthorization Act of 2026 H.R.8239 - SACRED Act S.4880, H.R…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Medical/Disease Research/Clinical Labs
$420,000
Spent on own lobbying
…Patients Deserve Price Tags Act H.R.5485 - Second Chance at Life Act H.R.8119- HOPE with Fertility Services Act S.4507, H.R.8784 - Bereaved Parents Rights Act S.4109 - Stem Cell Therapeutic and Research Reauthorization Act of 2026 S.3799, H.R.3302 - Healthy Start Reauthorization Act of 2026 H.R.8239 - SACRED Act S.4880, H.R…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Budget/Appropriations
$420,000
Spent on own lobbying
…H.R.6938 - Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriation Act, 2026 H.R.1 - Working Families Tax Cuts Act S.4109- Stem Cell Therapeutic and Research Reauthorization Act of 2026 S.3799, H.R.3302 - Healthy Start Reauthorization Act of 2026 S.4873 - Promoting Human Flourishi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL MARROW DONOR PROGRAM · lobbying firm or registrant: NATIONAL MARROW DONOR PROGRAM
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$300,000
Spent on own lobbying
Reauthorization of C.W. Bill Young Cell Transplantation Program (House and Senate), H.R. 5160/S. 4109.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTCT · lobbying firm or registrant: SMITHBUCKLIN CORPORATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Health Issues
$70,000
Paid to lobbying firm
Labor-HHS Appropriations Billing and Coding classifications CAR-T Therapy Clarifications H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160/S.4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act S. 4440/H.R. 3521 - The Clinical Trial Moderniza…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NMDP · lobbying firm or registrant: VAN SCOYOC ASSOCIATES
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Health Issues
$110,000
Paid to lobbying firm
….R.5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025, Cellular Transplant related issues and initiatives; and Reauthorization related issues S.4109, Stem Cell Therapeutic and Research Reauthorization Act of 2026, Entirety Transplant related issues, generally Monitor the following: Transplant courier issues…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MEDICAL COLLEGE OF WISCONSIN · lobbying firm or registrant: VAN SCOYOC ASSOCIATES
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Medical/Disease Research/Clinical Labs
$50,000
Paid to lobbying firm
…th and Human Services, and Education, and Related Agencies Appropriations Act, 2027, Healthcare research and development related issues; and NIH indirect costs S.4109, Stem Cell Therapeutic and Research Reauthorization Act of 2026, Entirety
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COLLEGE OF AMERICAN PATHOLOGISTS · lobbying firm or registrant: COLLEGE OF AMERICAN PATHOLOGISTS
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 15, 2026 · issue area: Health Issues
$180,107
Spent on own lobbying
…provider payments under the Medicare program S.4254 - A bill to amend the Public Health Service Act to provide for a health care workforce innovation program. S.4109 - A bill to reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes S.4110 - A bill to revise and extend health workforce progra…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COLLEGE OF AMERICAN PATHOLOGISTS · lobbying firm or registrant: COLLEGE OF AMERICAN PATHOLOGISTS
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted May 8, 2026 · issue area: Health Issues
$305,901
Spent on own lobbying
…provider payments under the Medicare program S.4254 - A bill to amend the Public Health Service Act to provide for a health care workforce innovation program. S.4109 - A bill to reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes S.4110 - A bill to revise and extend health workforce progra…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL MARROW DONOR PROGRAM · lobbying firm or registrant: NATIONAL MARROW DONOR PROGRAM
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$320,000
Spent on own lobbying
…ng Barriers for Caregivers (House and Senate), S. 1227/H.R. 2491. Reauthorization of C.W. Bill Young Cell Transplantation Program (House and Senate), H.R. 5160/S. 4109. Accelerating Kids Access to Care Act (House and Senate), S. 752/H.R. 1509. Credit for Caring Act (House and Senate), S. 925/H.R. 2036. Sickle Cell Disease Com…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTCT · lobbying firm or registrant: SMITHBUCKLIN CORPORATION
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$70,000
Paid to lobbying firm
…ccination of Immunosuppressed Patients H.R. 1509/S. 752, The Accelerating Kids Access to Care Act H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160/S.4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NMDP · lobbying firm or registrant: VAN SCOYOC ASSOCIATES
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 17, 2026 · issue area: Health Issues
$110,000
Paid to lobbying firm
….R.5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025, Cellular Transplant related issues and initiatives; and Reauthorization related issues S.4109, Stem Cell Therapeutic and Research Reauthorization Act of 2026, Entirety Monitor the following: Transplant courier issues FDA, Laboratory Developed Tests rela…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN ASSOCIATION OF BLOOD BANKS, DBA ASSOCIATION FOR THE ADVANCEMENT OF BLOO · lobbying firm or registrant: AMERICAN ASSOCIATION OF BLOOD BANKS, DBA ASSOCIATION FOR THE ADVANCEMENT OF BLOOD & BIOTHERAPIES
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 16, 2026 · issue area: Health Issues
Amount not reported
Stem Cell Therapeutic and Research Reauthorization Act (SCTRRA) (S. 4109/H.R. 5160)
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. View filing